279 results on '"Valderrama B"'
Search Results
2. 28P 3-year follow-up analysis of disease-free survival in CheckMate 274 by PD-L1 expression using tumor cell and combined positive scoring algorithms
3. Latest progress in molecular biology and treatment in genitourinary tumours
4. Impact of intestinal dysbiosis-related drugs on the efficacy of immune checkpoint inhibitors in clinical practice
5. SEOM clinical guideline for treatment of kidney cancer (2019)
6. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
7. Active surveillance as a successful management strategy for patients with clinical stage I germ cell testicular cancer
8. SEOM clinical guideline for treatment of muscle-invasive and metastatic urothelial bladder cancer (2018)
9. SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)
10. Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study
11. Influence of instrument conditions on the evaporation behavior of uranium dioxide with UV laser-assisted atom probe tomography
12. Bubble formation and Kr distribution in Kr-irradiated UO2
13. Résultats actualisés de survie sans maladie (DFS) de l’essai de phase 3 CheckMate 274, évaluant le nivolumab en adjuvant chez les patients atteints d’un carcinome urothélial infiltrant le muscle à haut risque de récidive (CUIM-HR) après exérèse complète
14. 1982P Post hoc analysis of outcomes according to prior chemotherapy (CT) response and platinum agent in the international SAUL study of atezolizumab (atezo) for urinary tract carcinoma (UTC).
15. 1768P Clinical outcomes with platinum-based chemotherapy after progression on frontline immunotherapy in metastatic urothelial cancer (mUC)
16. 1450MO Efficacy of a tailored approach with nivolumab and nivolumab/ipilimumab as immunotherapeutic boost in metastatic renal cell carcinoma: Final results of TITAN-RCC
17. 1474P Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)
18. 2021TiP INTerpath-005: Phase II study of pembrolizumab (pembro) with V940 (mRNA-4157) versus pembro with placebo (pbo) for adjuvant treatment of resected high-risk muscle-invasive urothelial carcinoma (MIUC)
19. 1966MO EV-302: Exploratory analysis of nectin-4 expression and response to 1L enfortumab vedotin (EV) + pembrolizumab (P) in previously untreated locally advanced or metastatic urothelial cancer (la/mUC)
20. 1654P TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
21. Costo de la gestión laboral en el proceso productivo de una empresa manufacturera trujillana. caso: Industrias Kel, C.A
22. Estados financieros previsionales como parte integrante de un conjunto completo de estados financieros en ambiente NIIF. Una propuesta en el marco de la lógica difusa
23. Seroprevalencia del virus de la rinoneumonitis en caballos (Equus caballus) del Peru
24. Immunotherapy in prostate cancer: review of the current evidence
25. Tumor carcinoide atípico solitario de timo: Una entidad inusual que no debemos olvidar
26. Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
27. Correction to: SEOM clinical guidelines for the treatment of metastatic prostate cancer (2017)
28. Infección cutánea diseminada por el virus del papiloma humano en paciente con trasplante renal
29. Cáncer de pulmón
30. LBA27 Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
31. Résultats actualisés de l’essai de phase 3 checkmate 274 évaluant nivolumab adjuvant (NIVO) versus placebo (PBO) chez les patients atteints de carcinome urothélial infiltrant le muscle (CUIM) à haut risque après résection complète
32. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma
33. 1888P 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
34. 2385P Long-term survival upon anti-PD-(L)1 monotherapy in metastatic urothelial cancer (mUC): A multicenter retrospective study
35. 2374P A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
36. 2359O Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
37. LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
38. LBA7 Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
39. 1793P PPROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Safety and toxicity profiles from the pilot phase
40. 1783P PROSTRATEGY: A SOGUG randomized trial of androgen deprivation therapy (ADT) plus docetaxel (dct) +/- nivolumab (nivo) or ipilimumab-nivolumab (ipi-nivo) in high-volume metastatic hormone-sensitive prostate cancer (hvHSPCa) - Efficacy results from the pilot phase
41. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
42. Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
43. CtDNA as a predictor of outcome in patients treated with neoadjuvant atezolizumab in muscle invasive urothelial cancer
44. 69P Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups
45. LBA27 Phase II multicenter, randomized study to evaluate efficacy and safety of avelumab with gemcitabine/carboplatin (CG) vs CG alone in patients with unresectable or metastatic urothelial carcinoma (mUC) who are ineligible to receive cisplatin-based therapy
46. 704MO Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone with 1L chemotherapy (CTx) for advanced urothelial carcinoma (UC): Subgroup analyses from JAVELIN Bladder 100
47. Tumor carcinoide atípico solitario de timo: Una entidad inusual que no debemos olvidar
48. Chapter 13 Bacterial hydrocarbon biosynthesis revisited
49. The Challenge of Managing Bladder Cancer and Upper Tract Urothelial Carcinoma: A Review with Treatment Recommendations from the Spanish Oncology Genitourinary Group (SOGUG)
50. 211MO EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.